MedPath

KEtogenic Diet and Its Multiple EffectS on Obesity

Not Applicable
Completed
Conditions
Obesity
Interventions
Other: Ketogenic diet
Other: Balanced diet
Registration Number
NCT05898204
Lead Sponsor
University of Roma La Sapienza
Brief Summary

The prevalence of obesity and metabolic disturbances is worryingly increasing worldwide, therefore the study of their pathophysiology is extremely important to find new strategies for their treatment. Obesity has a strong impact not only on the metabolism of the patients, but also may impact hormonal, inflammatory and immune profile, and profoundly influence the daily life of the patients. Weight loss may determine an amelioration of these parameters, but the impact of the diet composition aimed to weight loss on them has not been profoundly studied yet.

The aim of our research project is to study the effects of a ketogenic diet in comparison with an isocaloric balanced diet on weight loss and anthropometric parameters, quality of life, hormone profile, sleep, sexual function, circadian rhythm, inflammatory and immunological parameters in obese patients.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
24
Inclusion Criteria
  • Age between 18 and 65 years
  • BMI≥ 30 Kg/m2
Exclusion Criteria
  • Type 1 diabetes mellitus and latent autoimmune diabetes in adults
  • β-cell failure in type 2 diabetes mellitus
  • Use of sodium/glucose cotransporter 2 (SGLT2) inhibitors
  • Pregnancy and breastfeeding
  • Kidney failure and moderate-to-severe chronic kidney disease
  • Liver failure
  • Heart failure (NYHA III-IV)
  • Respiratory failure
  • Unstable angina, stroke or myocardial infarction in the last 12 months
  • Cardiac arrhythmias
  • Eating disorders and other severe mental illnesses, alcohol and substance abuse
  • Active/severe infections
  • Planned elective surgery or invasive procedures
  • Rare disorders: porphyria, carnitine deficiency, carnitine palmitoyltransferase deficiency, carnitine-acylcarnitine translocase deficiency, mitochondrial fatty acid β-oxidation disorders, pyruvate carboxylase deficiency

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Ketogenic diet armKetogenic dietKetogenic diet for a month, or a longer period if clinically necessary
Balanced diet armBalanced dietBalanced diet for a month, or a longer period if clinically necessary
Primary Outcome Measures
NameTimeMethod
Evaluation of changes in Perceived Quality of Life with SF-36 QuestionnairesAt baseline, at 15 days, at 30 days, at 60 days if the patient continued the diet

Assessment with the questionnaires Short Form Health Survey 36 (SF-36); scale of every item from 0 to 100; the higher the score, the better the quality of life

Evaluation of changes in Perceived Quality of Life with IWQOL-Lite QuestionnairesAt baseline, at 15 days, at 30 days, at 60 days if the patient continued the diet

Assessment with the questionnaires Impact of weight/Quality of Life-Lite (IWQOL-Lite); global scale from 0 to 100; the higher the score, the better the quality of life

Evaluation of changes in Perceived Quality of Life with "EQ-5D" QuestionnairesAt baseline, at 15 days, at 30 days, at 60 days if the patient continued the diet

Assessment with the questionnaires "EQ-5D"; scale of every item from 1 to 5; the higher the score, the worse the perceived problem

Secondary Outcome Measures
NameTimeMethod
Evaluation of changes in number of awakeningsAt baseline, at 30 days

Measurement with actigraphy

Evaluation of weight lossAt baseline, at 15 days, at 30 days, at 60 days if the patient continued the diet

Weight loss expressed in Kg

Evaluation of changes in hormonal profileAt baseline, at 30 days

Assessment of hormonal parameters, as cortisol, expressed in ug/dL

Evaluation of changes in hip circumferenceAt baseline, at 15 days, at 30 days, at 60 days if the patient continued the diet

Assessment of hip circumference, expressed in cm

Evaluation of changes in waist circumferenceAt baseline, at 15 days, at 30 days, at 60 days if the patient continued the diet

Assessment of waist circumference, expressed in cm

Evaluation of changes in Sexual Function in FemalesAt baseline, at 15 days, at 30 days, at 60 days if the patient continued the diet

Assessed with the questionnaire Female Sexual Function Index (FSFI); scale of every item from 1 to 5; the higher score, the better the sexual function

Evaluation of heightAt baseline

Assessment of height, expressed in cm

Evaluation of changes of peripheral blood mononuclear cellsAt baseline, at 30 days, at 60 days if the patient continued the diet

Number of cells of peripheral blood mononuclear cell subpopulations, expressed in number/mm3

Change in circadian rhythmAt baseline, at 30 days

Evaluation of change in midpoint of sleep, bedtime, sleep onset, rise time and circadian phase, expressed in hours

Evaluation of changes in sleep efficiencyAt baseline, at 30 days

Sleep efficiency expressed as a percentage; measurement with actigraphy

Evaluation of changes in clock genes expressionAt baseline, at 30 days

Evaluation of the expression of the clock genes in blood cells

Evaluation of changes in sleep parametersAt baseline, at 30 days

Evaluation of sleep fragmentation index and movement index, with actigraphy

Evaluation of changes of perceived sleepAt baseline, at 15 days, at 30 days, at 60 days if the patient continued the diet

Assessment with the questionnaires Pittsburgh Sleep Quality Index; global score on a scale from 0 to 21; the higher the score, the worse the sleep quality

Evaluation of changes of perceived sleepinessAt baseline, at 15 days, at 30 days, at 60 days if the patient continued the diet

Assessment with the questionnaires Epworth Sleepiness Scale (ESS); score on a scale from 0 to 24; the higher the score, the higher the sleepiness

Evaluation of changes in metabolic parametersAt baseline, at 30 days

Evaluation of changes in metabolic parameters, as glucose, triglycerides, cholesterol and HDL, expressed in mmol/L

Evaluation of changes in BMIAt baseline, at 15 days, at 30 days, at 60 days if the patient continued the diet

Weight and height will be combined to report BMI in kg/m\^2

Evaluation of changes in sexual function in malesAt baseline, at 15 days, at 30 days, at 60 days if the patient continued the diet

Assessed with the questionnaires International Index of Erectile Function (IIEF-5); scale from 5 to 25; the higher the score, the better the erectile function

Evaluation of changes in inflammationAt baseline, at 30 days, at 60 days if the patient continued the diet

Measurements of circulating cytokines, as interleukin 2 and interleukin 10, expressed in ng/mL

Evaluation of changes in sleep parameters (length)At baseline, at 30 days

Assessment with actigraphy of latency, total minutes in bed, total sleep time, wake after sleep onset, average awakening length, expressed in minutes

Trial Locations

Locations (1)

Sapienza University of Rome

🇮🇹

Roma, Italy

© Copyright 2025. All Rights Reserved by MedPath